// App-Quantinova.ai

P1-19-05 : Capivasertib (AZD5363) in combination with fulvestrant in PTEN-mutant ER+ metastatic breast cancer

Researchers

Presenter

  • Lillian M Smyth

Principal Investigators

  • Funda Meric-Bernstam

  • Peter Kabos

  • Iben Spanggaard

  • Ana Lluch

  • Alison Schram

  • Andrea Varga

  • Andrea Wong

  • Helen Ambrose

  • Alan Barnicle

  • T. Hedley Carr

  • Elza C de Bruin

  • Carolina Salinas-Souza

  • Andrew Foxley

  • Joana Hauser

  • Justin PO Lindemann

  • Rhiannon Maudsley

  • Robert McEwen

  • Michele Moschetta

  • Martine Roudier

  • Gaia Schiavon

  • Pedram Razavi

  • Udai Banerji

  • Sarat Chandarlapaty

  • Jos Baselga

  • David M Hyman

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Segal Cancer Center/Jewish General Hospital, McGill University, Montreal, QC, Canada

  • 1.MD Anderson Cancer Center, Houston, TX

  • University of Colorado Cancer Center, Aurora, CO

  • Finsens Center, Copenhagen, Denmark

  • Clinic Hospital of Valencia,Valencia,Spain

  • Institut Gustave-Roussy, Villejuif, France

  • National University Hospital Singapore, Singapore, Singapore

  • Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

Locations

  • United States

  • Canada

  • Denmark

  • Spain

  • France

  • Singapore

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • Fulvestrant

  • AZD-5363

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • I

Study Id's

  • NCT01226316

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved